Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 310
- 试验地点
- 1
- 主要终点
- Prognostic value of the markers of interest (CXCL4, CXCL4L1 et CXCR3)
研究概览
简要总结
Despite novel treatment options, Renal Cell Carcinoma (RCC) has been characterized by a constant increase in its mortality and consequently requires an important involvement in translational research.
The aim of this study is to evaluate the interest of CXCL4, CXCL4L1 and CXCR3 as biomarkers in localized, locally advanced or metastatic RCC. Indeed these chemokines have shown anti-angiogenic and anti-tumor properties in experimental models and may be particularly interesting for prognostic and predictive purposes.
详细描述
Based on a physiopathological rationale, the use of RCC-directed antiangiogenic therapies into clinical practice leads to conclusive results and makes RCC a particularly well-suited tumor type to study factors involved in the angiogenic process. Furthermore the intensive use of targeted therapies in clinical practice raised new questions about their management.
Therefore the identification of new molecular biomarkers is important:
- to improve the precision of prognostic models currently based on clinical, biological or histopathological variables
- to identify high risk patients that could benefit from an adjuvant treatment or a closer postoperative follow-up
- to predict the response to antiangiogenic therapies and therefore identify the drug which is likely to be the most effective within an ever increasing pharmacopeia
- to follow the therapy as precisely as possible, predict or attest the disease progression justifying a therapeutic modification
Low CXCL4, CXCL4L1 and CXCR3 tumor expression levels are associated with bad prognosis factors in RCC. Consequently their interest in RCC is worth being evaluated, in two subgroups : Localized / locally advanced renal cell carcinoma and Metastatic renal cell carcinoma.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with localized, locally advanced or metastatic Renal Cell Carcinoma :
- •having a radical or partial nephrectomy
- •or treated by RCC-directed targeted therapy
- •Patients who have signed and dated an informed consent form with the investigator
排除标准
- •under 18 years old
结局指标
主要结局
Prognostic value of the markers of interest (CXCL4, CXCL4L1 et CXCR3)
时间窗: 3 years
Prognostic value of the markers of interest (CXCL4, CXCL4L1 et CXCR3) will be evaluated by the association of these markers with time to event occurrence. Localized or locally advanced renal cell carcinoma group: * local recurrence * contralateral recurrence * extra-renal distant recurrence (metastatic progression) * specific cancer death * nonspecific cancer death Metastatic renal cell carcinoma group : * local recurrence for patients who underwent a nephrectomy * contralateral reccurence * metastatic progression * specific cancer death * nonspecific cancer death
次要结局
- Predictive value of therapeutic response(3 years)